Silevertinib Phase 2 Data: 60% ORR, 86% CNS ORR – But Single-Arm Caveats Remain

What happened

Black Diamond Therapeutics reported Phase 2 data for silevertinib showing a 60% overall response rate and 86% CNS response rate in EGFR-mutant NSCLC, a notable improvement over earlier ~36-42% ORR. Despite these encouraging figures, the data come from a small, single-arm cohort and lack a comparator, limiting interpretability. The stock trades below cash value, but the company remains a single-asset micro-cap with no pivotal trials underway and intense competition from larger players targeting similar resistance mutations. Cash runway extends into 4Q27, but substantial additional capital will be needed for registrational trials. The positive efficacy signal increases the probability of success, but the high binary risk and absence of a de-risked regulatory path keep the thesis speculative.

Implication

If silevertinib data are corroborated in larger cohorts and FDA feedback supports a feasible registrational path, the risk/reward could shift favorably. However, investors should wait for Phase 2 frontline data and regulatory clarity in 1H26 before building a core position, given dilution risk and competitive threats.

Thesis delta

The earlier DeepValue report maintained a WAIT stance, citing binary risk and lack of pivotal data. The new 60% ORR/86% CNS ORR data, while still early, meaningfully improve the asset's probability of technical and regulatory success. This supports upgrading to POTENTIAL BUY if upcoming frontline data and FDA guidance are favorable, though the single-asset concentration and capital needs remain major risks.